Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina

Smith, A.; English, K; Malkin, Christopher J.; Jones, Richard D.; Jones, T Hugh; Channer, Kevin S.

doi:10.1530/eje.1.01848

Cited by 45 publications

(32 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, testosterone does not adversely affect blood coagulation status. (38) In the present study we have observed lower clotting time in males than females.…”

Section: Discussionsupporting

confidence: 54%

Bleeding time and Clotting Time in Healthy Male and Female College Students of Karukutty Village, Kerala

Kumar¹,

Vk²,

George³

et al. 2013

Health Prospect

View full text Add to dashboard Cite

BackgroundIt was reported that females are having high Bleeding time and clotting time than males. The reason for prolonged bleeding and clotting time in females is not clear. The studies on Bleeding time and Clotting time in healthy male and female college students of Kerala are inadequate. Therefore the present study was undertaken to measure and compare bleeding time and clotting time in male and female college students. MethodologyTwo hundred and twenty two healthy male and female college students, were enrolled in the present study. Bleeding time was estimated by Duke Method and clotting time was estimated by capillary tube method. ResultsMean age of the participants of present study is 19±1. We have observed higher bleeding time (BT) and clotting time (CT) in females (155.45±34.91 seconds and 318.18±64.40 seconds) than males (96.06±55.05 seconds and 223.01±50.74 seconds) which is statistically significant (p value <0.001). Minimum and Maximum bleeding time observed in females is 2minutes and 4 minutes respectively while in males, it is 30 seconds and 3 minutes 30 seconds respectively. Minimum and maximum clotting time observed in females is 3minutes 30 seconds and 10 minutes respectively while in males, it is 2 minutes 30 seconds and 5 minutes respsectively. ConclusionOur study suggests that bleeding and clotting time are slightly higher in females. We recommend further detailed study in this area.

show abstract

“…However, testosterone does not adversely affect blood coagulation status. (38) In the present study we have observed lower clotting time in males than females.…”

Section: Discussionsupporting

confidence: 54%

Bleeding time and Clotting Time in Healthy Male and Female College Students of Karukutty Village, Kerala

Kumar¹,

Vk²,

George³

et al. 2013

Health Prospect

View full text Add to dashboard Cite

show abstract

“…There is a positive correlation with tissue plasminogen activator (tPA) which is one of the major fi brinolytic agents (Glueck et al 1993). Interventional trials have shown a neutral effect of physiological testosterone replacement on the major clotting factors (Smith et al 2005) but supraphysiological androgen administration can produce a temporary mild pro-coagulant effect (Anderson et al 1995).…”

Section: Figurementioning

confidence: 99%

Testosterone for the aging male; current evidence and recommended practice

Stanworth

Jones²

2008

CIA

125

View full text Add to dashboard Cite

An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. The diagnosis of LOH requires biochemical and clinical components. Controversy in defi ning the clinical syndrome continues due to the high prevalence of hypogonadal symptoms in the aging male population and the non-specifi c nature of these symptoms. Further controversy surrounds setting a lower limit of normal testosterone, the limitations of the commonly available total testosterone result in assessing some patients and the unavailability of reliable measures of bioavailable or free testosterone for general clinical use. As with any clinical intervention testosterone treatment should be judged on a balance of risk versus benefi t. The traditional benefi ts of testosterone on sexual function, mood, strength and quality of life remain the primary goals of treatment but possible benefi cial effects on other parameters such as bone density, obesity, insulin resistance and angina are emerging and will be reviewed. Potential concerns regarding the effects of testosterone on prostate disease, aggression and polycythaemia will also be addressed. The options available for treatment have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations.

show abstract

“…Physiological testosterone replacement has been reported in a number of trials to improve lipid profiles, increase insulin sensitivity, and reduce visceral fat, clotting and inflammatory profiles (reviewed in (7)(8)(9)). Importantly, no adverse effects of testosterone replacement therapy on coagulation have been demonstrated in men with chronic stable angina (10). Furthermore, animal studies have shown that testosterone replacement inhibits the development and progression of atheroma (11).…”

Section: Introductionmentioning

confidence: 99%

Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men

Mathur

Malkin²,

Saeed³

et al. 2009

European Journal of Endocrinology

135

View full text Add to dashboard Cite

Introduction: In short-term studies, testosterone replacement therapy has been shown to protect male subjects from exercise-induced ischaemia and modify cardiovascular risk factors such as insulin resistance, fat mass and lipid profiles. Methods: This randomised parallel group controlled trial was designed to assess the treatment effect of testosterone therapy (Nebido) compared with placebo in terms of exercise-induced ischaemia, lipid profiles, carotid intima-media thickness (CIMT) and body composition during 12 months treatment in men with low testosterone levels and angina. Results: A total of 15 men were recruited but 13 (nZ13) reached adequate duration of follow-up; seven were treated with testosterone and six with placebo. Testosterone increased time to ischaemia (129G48 s versus 12G18, PZ0.02) and haemoglobin (0.4G0.6 g/dl versus K0.03G0.5, PZ0.04), and reduced body mass index (K0.3 kg/m 2 versus 1.3G1, PZ0.04) and triglycerides (K0.36

show abstract

Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina

Cited by 45 publications

References 42 publications

Bleeding time and Clotting Time in Healthy Male and Female College Students of Karukutty Village, Kerala

Bleeding time and Clotting Time in Healthy Male and Female College Students of Karukutty Village, Kerala

Testosterone for the aging male; current evidence and recommended practice

Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men

Contact Info

Product

Resources

About